ImmunoGen AI

Executive Summary

ImmunoGen AI is a San Francisco-based biotechnology company that harnesses artificial intelligence and machine learning to accelerate the discovery and development of novel antibody therapeutics for oncology. Founded in 2020, the company has raised $65 million in funding and employs a team of 1-50 experts. Its proprietary computational platform designs antibodies with optimized binding, specificity, and developability, aiming to identify novel targets and streamline the pre-clinical pipeline. By integrating AI into antibody engineering, ImmunoGen AI seeks to reduce the time and cost of bringing new cancer therapies to patients. The company is currently in the platform stage, focusing on advancing its internal programs and establishing strategic partnerships. With a strong backing from investors and a clear need for more efficient antibody discovery, ImmunoGen AI is positioned to play a key role in the next generation of cancer treatments.

Upcoming Catalysts (preview)

• Q3 2026Nomination of lead clinical candidate65% success
• Q2 2026Strategic partnership or licensing deal with major pharma50% success
• Q4 2026Series B or additional funding round70% success